Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Moberg Derma has started recruiting patients for a clinical Phase III trial of the K301 product candidate to treat seborrheic dermatitis of the scalp.
Subscribe to our email newsletter
The company plans to include 180 patients in the study at around 20 clinics in Sweden. The results from the trial are expected in the second half of 2008.
Peter Wolpert, CEO of Moberg Derma, said: “We recently received the approval from the Swedish Medical Products Agency and Ethical Committee and will now initiate our second Phase III study. If the promising data from our previous Phase II trial can be reproduced in this larger study, we will be able to offer patients a novel and efficacious topical treatment for seborrheic dermatitis of the scalp.”